Novartis and Sanofi-Genzyme have co-led a first funding round for NeuroVia, which will use the cash to advance development of a drug for a rare genetic neurological disease.
US-based biopharmaceutical company NeuroVia closed a $14m series A round yesterday that was co-led by pharmaceutical firm Novartis and biotech developer Sanofi-Genzyme, through subsidiaries Novartis Venture Fund and Sanofi-Genzyme BioVentures.
BioMed Ventures, the venture capital arm of real estate investment trust BioMed Realty and VC firm Enso Ventures also took part in the funding round, which had achieved a first close at $11.45m in late 2015 with the support of Novartis and Sanofi-Genzyme.
NeuroVia is working on treatments for a…
